Listed by the USPTO as MYERS, CARLA J
Tech Center 1600 • Art Units: 1600 1613 1634 1671 1678 1682
This examiner grants 50% of resolved cases
MYERS, CARLA J handles cases in tech center 1600 and art unit 1600. The profile covers 1043 resolved cases, with an allowance rate of 49.6%, an interview lift of 45.9%, and a median time to allowance of 1139 days.
The 49.6% allowance rate indicates a mixed outcome record, while the 45.9% interview lift is a strong separate signal for prosecution tactics. Interviews may merit deliberate use alongside focused claim amendments and arguments. The listed companies are Illumina Inc., The Children's Hospital of Philadelphia, and BIOASTER. The listed firms are HOWSON & HOWSON LLP, OLIFF PLC, and CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18717006 | SINGLE-CELL CULTURE AND SEQUENCING WITH LIPID-MODIFIED OLIGOS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18706182 | IMMUNOTHERAPY TARGETING | Non-Final OA | The Regents of the University of California |
| 18606690 | METHODS, COMPOSITIONS, AND SYSTEMS FOR CAPTURING PROBES AND/OR BARCODES | Non-Final OA | 10x Genomics, Inc. |
| 18023249 | TARGET MEASUREMENT METHOD, TARGET MEASUREMENT DEVICE, TARGET MEASUREMENT APPARATUS, AND TARGET MEASUREMENT KIT | Non-Final OA | Yokogawa Electric Corporation |
| 18540667 | METHODS AND COMPUTER PRODUCTS FOR MEASURING THE AMOUNT OF CELLS OF A PARTICULAR CELL LINEAGE | Non-Final OA | The Chinese University of Hong Kong |
| 18265029 | A METHOD FOR CLASSIFYING THE GUT INFLAMMATION STATUS IN AVIAN SPECIES | Final Rejection | Evonik Operations GmbH |
| 18044471 | GENETIC ALTERATIONS ASSOCIATED WITH EOSINOPHILIC ESOPHAGITIS AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17641502 | COMPOSITIONS COMPRISING RARE GENETIC SEQUENCE VARIANTS ASSOCIATED WITH PULMONARY FUNCTION AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF ASTHMA IN AFRICAN AMERICAN PATIENTS | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17429281 | ISOLATION AND DETECTION OF EXOSOME-ASSOCIATED MICROBIOME FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES | Non-Final OA | Board of Regents, The University of Texas System |
| 18290138 | CD274 MUTATIONS FOR CANCER TREATMENT | Non-Final OA | Foundation Medicine, Inc. |
| 18420482 | INFERRING MICROORGANISM OF ORIGIN FOR ANTIMICROBIAL RESISTANCE MARKERS IN TARGETED METAGENOMICS | Non-Final OA | Illumina, Inc. |
| 17026069 | METHODS AND COMPOSITIONS FOR IDENTIFYING LIGANDS ON ARRAYS USING INDEXES AND BARCODES | Non-Final OA | ILLUMINA, INC. |
| 17840801 | METHOD OF DIAGNOSIS OF HEMOPHILIA | Final Rejection | Machaon Diagnostics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy49.6% of resolved applications examined by Carla J Myers were allowed (1,043 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +45.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Carla J Myers took 1,139 days on average from filing to allowance.
Carla J Myers examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).